Year Founded
2019
Ownership
Private
Employees
~50
Therapeutic Areas
Rare DiseasesNeurologyMetabolic DisordersOncology
Stage
Preclinical
Modalities
Gene therapySmall molecule

Pretzel Therapeutics General Information

Company launched in 2022 with platform technologies in gene correction, genome expression modulation, and mitochondrial quality control

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Waltham, Massachusetts
United States

Drug Pipeline

No pipeline data available

For full access to Pretzel Therapeutics's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Pretzel Therapeutics Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Pretzel Therapeutics's complete valuation and funding history, request access »

Pretzel Therapeutics Investors

ARCH Venture Partners
Investor Type: Venture Capital
Holding: Minority
Mubadala Capital
Investor Type: Venture Capital
Holding: Minority
HealthCap
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 11 investors. Get the full list »